test header

Immunology

AAD

Orlando

Poster

Achievement of treat-to-target thresholds for overall psoriasis response with deucravacitinib: post hoc, subgroup analysis of the randomized, double-blind, placebo-controlled phase 3b/4 PSORIATYK SCALP trial

Diamant Thaçi, Kristina Callis Duffin, Linda Stein Gold, Leon Kircik, Andrew Napoli, Chun-Yen Cheng, Rachel Dyme, Eugene Balagula, Matthias Augustin.

Poster

Deucravacitinib is associated with improvements in Dermatology Life Quality Index in patients with moderate to severe scalp psoriasis: an analysis of PSORIATYK SCALP, a randomized, double-blinded, placebo-controlled, phase 3b/4 trial

Steven R. Feldman, MD, PhD, Matthias Hoffmann, MD, Jerry Bagel, MD, Matthias Augustin, MD, David M. Pariser, MD, Andrew Napoli, PhD, Eugene Balagula, MD, Rachel Dyme, MD, Brandon Becker, PhD, MPH, Chun-Yen Cheng, MS, Christopher E.M. Griffiths, MD.

Poster

Efficacy of deucravacitinib in psoriasis by baseline total body surface area: post hoc analysis of the randomized, double-blind, placebo-controlled, phase 3b/4 PSORIATYK SCALP trial

Andrew Blauvelt, Diamant Thaçi, David M. Pariser, Andrew Napoli, Eugene Balagula, Chun-Yen Cheng, Rachel Dyme, Linda Stein Gold, Mark Lebwohl.

Poster

Moderate to severe scalp psoriasis is associated with severe impact on quality of life: an analysis of patient-reported outcomes in PSORIATYK SCALP, a scalp-specific phase 3b/4 trial with deucravacitinib

Steven R. Feldman, MD, PhD, Anne-Bénédicte Duval-Modeste, MD, Amy Foulkes, MD, PhD, Wojciech Baran, MD, PhD, Andrew Napoli, PhD, Eugene Balagula, MD, Chun-Yen Cheng, MS, Brandon Becker, PhD, MPH, Rachel Dyme, MD, Diamant Thaçi, MD, PhD.

Oral

Real-world effectiveness of deucravacitinib in patients with plaque psoriasis: a 6-month analysis of quality of life and symptom burden from the Registry of Psoriasis Health Outcomes: A Longitudinal Real-World Collaboration Study (RePhlect)

Bruce Strober, MD, MMSc, April W. Armstrong, MD, MPH, Kim A. Papp, MD, PhD, Adam Sima, PhD, Melinda Gooderham, MD, Stefan Varga, PharmD, MS, Yichen Zhong, PhD, Joe Zhuo, PhD, Joseph F. Merola, MD, MMSc, Alice B. Gottlieb, MD, PhD, Andrew Napoli, PhD, Mark Lebwohl, MD.

Poster

Real-world effectiveness of deucravacitinib in patients with plaque psoriasis: a 6-month analysis of skin clearance from the RePhlect Registry

Mark Lebwohl, MD,1 April W. Armstrong, MD, MPH,2 Stefan Varga, PharmD, MS,3 Yichen Zhong, PhD,3 Joseph F. Merola, MD, MMSc,4 Adam Sima, PhD,5 Melinda Gooderham, MD,6-8 Kim A. Papp, MD, PhD,9,10 Alice B. Gottlieb, MD, PhD,11 Andrew Napoli, PhD,3 Bruce Strober, MD, MMSc12

Poster

The evaluation of adequate clinical response to systemic therapy as measured by the Merit-based Incentive Payment System (MIPS) #410 psoriasis quality measure in patients treated with deucravacitinib: a RePhlect 6-month follow-up study

April W. Armstrong, MD, MPH, Mark Lebwohl, MD, Stefan Varga, PharmD, MS, Joe Zhuo, PhD, Melinda Gooderham, MD, Robert R. McLean, DSc, MPH, Kim A. Papp, MD, PhD, Joseph F. Merola, MD, MMSc, Alice B. Gottlieb, MD, PhD, Andrew Napoli, PhD, Bruce Strober, MD, MMSc.